Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 2/20 | 0.55 |
| ▸ | ANPEP | P15144 | 2/20 | 0.55 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.55 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.55 |
| ▸ | IL1RN | P18510 | 4/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.52 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bestatin Methyl Ester SCHEMBL9574604 | 0.91 | ANPEP (0.61) | LAP3ANPEPRNPEPDNPEPIL1RN | |
| Bestatin Methyl Ester SCHEMBL15261304 | 0.91 | ANPEP (0.61) | LAP3ANPEPRNPEPDNPEPIL1RN | |
| Bestatin Methyl Ester SCHEMBL12381043 | 0.91 | ANPEP (0.61) | LAP3ANPEPRNPEPDNPEPIL1RN | |
| SCHEMBL17278281 | 0.88 | METAP2 (0.55) | LAP3ANPEPRNPEPDNPEPIL1RN | |
| SCHEMBL22703104 | 0.88 | LAP3 (0.55) | LAP3ANPEPRNPEPDNPEPIL1RN | |
| Ubenimex SCHEMBL25971 | 0.87 | MME (0.66) | LAP3ANPEPRNPEPDNPEPMME | |
| Ubenimex SCHEMBL9247599 | 0.87 | MME (0.66) | LAP3ANPEPRNPEPDNPEPMME | |
| Ubenimex SCHEMBL22632072 | 0.87 | MME (0.66) | LAP3ANPEPRNPEPDNPEPMME | |
| Ubenimex SCHEMBL7944 | 0.87 | MME (0.66) | LAP3ANPEPRNPEPDNPEPMME | |
| Ubenimex SCHEMBL17889224 | 0.87 | MME (0.66) | LAP3ANPEPRNPEPDNPEPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062258-A1 | Heterocyclic derivatives | MERCK PATENT GMBH (DE) | 2022-03-03 | — | — | US | disclosed |
| WO-2021229237-A1 | CYCLOSPORINE ANALOGUES | UCL BUSINESS LTD (GB) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062258-A1 | Heterocyclic derivatives | XIAP, UBQLN1, UBQLN2 | LAP3 3616/4885ANPEP 4413/4885RNPEP 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.